Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients’ and Physicians’ View

Author:

Dubinsky Marla C1,Watanabe Kenji2,Molander Pauliina3,Peyrin-Biroulet Laurent4,Rubin Michele5,Melmed Gil Y6,Deuring J Jasper7,Woolcott John8,Cappelleri Joseph C9,Steinberg Kathy10,Connor Susan11

Affiliation:

1. Icahn School of Medicine at Mount Sinai, New York, New York, USA

2. Hyogo College of Medicine, Hyogo, Japan

3. Abdominal Center, Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

4. Nancy University Hospital, Lorraine University, Vandœuvre-lès-Nancy, France

5. University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, Illinois, USA

6. Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA

7. Pfizer Inc, Rotterdam, The Netherlands

8. Pfizer Inc, Collegeville, Pennsylvania, USA

9. Pfizer Inc, Groton, Connecticut, USA

10. The Harris Poll, New York, New York, USA

11. Liverpool Hospital, South Western Sydney Clinical School, University of New South Wales, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia

Abstract

Abstract Background The Ulcerative Colitis (UC) Narrative is a global patient and physician survey aimed at identifying the impact of UC and comparing and contrasting perceptions of UC burden and management approaches. Methods Surveys of patients with UC (self-reported diagnosis; n = 2100) and physicians (n = 1254) were completed across 10 countries by The Harris Poll between August 2017 and February 2018. Questionnaires covered multiple aspects of UC, including diagnosis, treatment, and impact on patient quality of life, in addition to standard demographic information. Descriptive statistics are reported. Results The majority of patients (82%) had moderate to severe UC (based on medication history; those who had only ever taken 5-aminosalicylates were excluded); 67% described their UC as controlled with few to no symptoms. On average, patients experienced 4.3 flares (standard deviation, 7.4) in the past year. Diagnostic delay was on average 2.0 years (standard deviation, 5.4); 42% of patients waited ≥1 year. Most patients (65%) felt that UC controlled their life rather than them controlling their disease. Because of the fear of repercussions, many patients had not disclosed their UC to their employer. Discussion of the emotional impact of UC during routine appointments was less of a priority for physicians, compared with patients. Conclusions The data from this global survey highlight that patients with UC experience diagnostic delay, poor disease control, and adverse impact on their quality of life. Patients report UC to be a mentally exhausting condition; however, emotional and mental health issues are infrequently discussed at routine appointments.

Funder

Pfizer Inc

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3